BCG scarring and improved child survival: a combined analysis of studies of BCG scarring.
BCG Vaccine
/ adverse effects
Cause of Death
Child
Child Mortality
Child, Preschool
Cicatrix
/ etiology
Confounding Factors, Epidemiologic
Endemic Diseases
/ prevention & control
Follow-Up Studies
Guinea-Bissau
/ epidemiology
Humans
Infant
Infant, Newborn
Mass Vaccination
/ adverse effects
Nutritional Status
Tuberculosis
/ prevention & control
BCG scar
Bacille Calmette-Guérin
child survival
nonspecific effects of vaccines
Journal
Journal of internal medicine
ISSN: 1365-2796
Titre abrégé: J Intern Med
Pays: England
ID NLM: 8904841
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
28
10
2019
revised:
11
03
2020
accepted:
15
03
2020
pubmed:
18
4
2020
medline:
23
2
2021
entrez:
18
4
2020
Statut:
ppublish
Résumé
Bacillus Calmette-Guérin (BCG) vaccine against tuberculosis (TB) is recommended at birth in TB-endemic areas. Currently, BCG vaccination programmes use "BCG vaccination coverage by 12 months of age" as the performance indicator. Previous studies suggest that BCG-vaccinated children, who develop a scar, have better overall survival compared with BCG-vaccinated children, who do not develop a scar. We summarized the available studies of BCG scarring and child survival. A structured literature search for studies with original data and analysis of BCG scarring and mortality were performed. Combined analyses on the effect of BCG scarring on overall mortality. We identified six studies covering seven cohorts, all from Guinea-Bissau, West Africa, with evaluation of BCG scarring amongst BCG-vaccinated children and follow-up for mortality. Determinants of BCG scarring were BCG strain, intradermal injection route, size of injection wheal, and co-administered vaccines and micronutrients. In a combined analysis, having a BCG scar vs. no BCG scar was associated with a mortality rate ratio (MRR) of 0.61 (95% CI: 0.51-0.74). The proportion with a BCG scar varied from 52 to 93%; the estimated effect of a BCG scar was not associated with the scar prevalence. The effect was strongest in the first (MRR = 0.48 (0.37-0.62)) and second (MRR = 0.63 (0.44-0.92)) year of life, and in children BCG-vaccinated in the neonatal period (MRR = 0.45 (0.36-0.55)). The effect was not explained by protection against TB. Confounding and genetic factors are unlikely to explain the strong association between BCG scarring and subsequent survival. Including "BCG scar prevalence" as a BCG vaccination programme performance indicator should be considered. The effect of revaccinating scar-negative children should be studied.
Substances chimiques
BCG Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
614-624Informations de copyright
© 2020 The Association for the Publication of the Journal of Internal Medicine.
Références
Calmette A. Preventive vaccination against tuberculosis with BCG. Proc R Soc Med 1931; 24: 1481-90.
Naeslund C. Resultats Des Experiences de Vaccination Par le BCG Poursuivies Dans le Norrbotten (Suède) (Septembre 1927 - Décembre 1931). Vaccination Préventive de la Tuberculose de l'homme et des animaux par le B C G Rapports et Documents Provenant Des Divers Pays (la France exceptée) transmis à l'Institut Pasteur en 1932. Paris, France: Mason and Cie; 1932: 274-81.
Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ 2000; 321: 1435-8.
Garly ML, Balé C, Martins CL et al. BCG vaccination among West African infants is associated with less anergy to tuberculin and diphtheria-tetanus antigens. Vaccine 2001; 20: 468-74.
Garly ML, Martins CL, Balé C et al. BCG scar and positive tuberculin reaction and reduced infant and childhood mortality in West Africa: A non-specific beneficial effect of BCG? Vaccine 2003; 21: 2782-90.
Roth A, Gustafson P, Nhaga A et al. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol 2005; 34: 540-7.
Roth A, Sodemann M, Jensen H et al. Tuberculin reaction, BCG scar, and lower female mortality. Epidemiology 2006; 17: 562-8.
Storgaard L, Rodrigues A, Martins C et al. Development of BCG scar and subsequent morbidity and mortality in rural Guinea-Bissau. Clin Infect Dis 2015; 61: 950-9.
Timmermann CA, Biering-Sørensen S, Aaby P et al. Tuberculin reaction and BCG scar: association with infant mortality. Trop Med Int Health 2015; 20: 1733-44.
Berendsen M, Øland CB, Bles P et al. Maternal priming: BCG-scarring in the mother enhances the survival of children with a BCG-scar. JPIDS 2019.
Roth A, Sodemann M, Jensen H et al. Vaccination technique, PPD reaction and BCG scarring in a cohort of children born in Guinea Bissau 2000-2002. Vaccine 2005; 23: 3991-98.
Frankel H, Byberg S, Bjerregaard-Andersen M et al. Different effects of BCG strains - A natural experiment evaluating the impact of the Danish and the Russian BCG strains on morbidity and scar formation in Guinea-Bissau. Vaccine 2016; 34: 4586-93.
Funch KM, Thysen SM, Rodrigues A et al. Determinants of BCG scarification among children in rural Guinea-Bissau: A prospective cohort study. Hum Vacc Immunotherapeut 2018; 14: 2434-42.
Anderson EJ, Webb EL, Mawa PA et al. The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine 2012; 30: 2083-9.
Aaby P, Gustafson P, Roth A et al. Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau. Vaccine 2006; 24: 5718-25.
Corrah T, Byass P, Jaffar S et al. Prior BCG vaccination improves survival of Gambian patients treated for pulmonary tuberculosis. Trop Med Int Health 2000; 5: 413-7.
Pala K, Gerçek H, Taş TA, Çakir R, Özgüç S, Yildiz T. 30 Years retrospective review of tuberculosis cases in a tuberculosis dispensary In Bursa/Nilufer, Turkey (1985-2014). Medit J Hematol Infect Dis 2015; 8: 1985-2014.
Ritz N, Dutta B, Donath S et al. The influence of bacilli Calmette-Guérin vaccine strain on the immune response against tuberculosis: a randomized trial. Am J Respir Crit Care Med 2012; 185: 213-22.
Higgins JPT, Soares-Weiser K, López-López JÁ et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ 2016; 355: i5170.
Cornfield J, Haenszel W, Hammond EC, Lilienfield AM, Shimkin MB, Wynder EL. Smoking and lung cancer: recent evidence and a discussion of some questions. J Natl Cancer Inst 1959; 22: 173-203.
Roth A, Jensen H, Garly ML et al. Low birth weight infants and Calmette-Guérin bacillus vaccination at birth: community study from Guinea-Bissau. PIDJ 2004; 23: 544-50.
Benn CS, Fisker AB, Rieckmann A, Jensen AG, Aaby P. How to evaluate potential non-specific effects of vaccines: the quest for randomized trials or time for triangulation? Expert Rev Vaccines 2018; 17: 411-20.
Biering-Sørensen S, Aaby P, Lund N et al. Early BCG and neonatal mortality among low-birth-weight infants: A randomised controlled trial. Clin Inf Dis 2017; 65: 1183-90.
Jayaraman K, Adhisivam B, Nallasivan S et al. Two randomized trials of the effect of the russian strain of bacillus calmette-guerin alone or with oral polio vaccine on neonatal mortality in infants weighing <2000 g in India. Pediatr Infect Dis J 2019; 38: 198-202.
Curtis N. BCG vaccination and all-cause neonatal mortality. Pediatr Infect Dis J 2019; 38: 195-7.
Angelidou A, Conti MG, Diray-Arce J et al. Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. Vaccine 2020; 38: 2229-40.
Schaltz-Buchholzer F, Bjerregaard-Andersen M, Øland CB et al. Early vaccination with BCG-Denmark or BCG-Japan vs. BCG-Russia to healthy newborns in Guinea-Bissau: a randomized controlled trial. Clin Infect Dis 2019. pii: ciz1080. https://doi.org/10.1093/cid/ciz1080.
Kleinnijenhuis J, Quintin J, Preijers F et al. Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012; 109: 17537-42.
Benn CS, Netea MG, Selin LK, Aaby P. A small jab - a big effect: nonspecific immunomodulation by vaccines. Trends Immunol 2013; 34: 431-9.
Arts RJW, Moorlag SJCFM, Novakovic B et al.BCG Vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 2018; 23: 89-100.e5.
Thysen SM, Byberg S, Pedersen M et al. BCG coverage and barriers to BCG vaccination in Guinea-Bissau: an observational study. BMC Public Health 2014; 14: 1037.
Clark A, Sanderson C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009; 373: 1543-9.
Roth A, Benn CB, Ravn H et al. Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. BMJ 2010; 340: c671.
Benn CS, Fisker AB, Whittle HC, Aaby P. Revaccination with live attenuated vaccines confer additional beneficial nonspecific effects on overall survival: a review. EBioMedicine 2016; 10: 312-7.